Mitomycin clinical trials
Also written Mutamycin and Mitosol.
How each study uses Mitomycin is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Mitomycin studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 24 Aug 1981 · MUTAMYCIN · ANDA 062336 (FDA, Drugs@FDA)
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
131 studies that test it; most in 2014 (10); 1 more planned to start later
| Year | Studies |
|---|---|
| 1992 | 1 |
| 1994 | 2 |
| 1996 | 2 |
| 1997 | 2 |
| 1998 | 2 |
| 1999 | 4 |
| 2001 | 3 |
| 2002 | 1 |
| 2003 | 3 |
| 2004 | 3 |
| 2005 | 4 |
| 2006 | 5 |
| 2007 | 3 |
| 2008 | 2 |
| 2009 | 7 |
| 2010 | 1 |
| 2011 | 2 |
| 2012 | 5 |
| 2013 | 4 |
| 2014 | 10 |
| 2015 | 8 |
| 2016 | 6 |
| 2017 | 7 |
| 2018 | 3 |
| 2019 | 4 |
| 2020 | 6 |
| 2021 | 5 |
| 2022 | 4 |
| 2023 | 6 |
| 2024 | 4 |
| 2025 | 4 |
| 2026 | 8 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 10 · Other 124
UroGen Pharma Ltd. (7) · Shahid Beheshti University of Medical Sciences (5) · National Cancer Institute (NCI) (4) · Memorial Sloan Kettering Cancer Center (3) · Fox Chase Cancer Center (3) · Radiation Therapy Oncology Group (3) · M.D. Anderson Cancer Center (3) · University of California, San Francisco (3)
Often tested with
Tested in the same studies.
Fluorouracil (25) · Cisplatin (22) · Gemcitabine (13) · Capecitabine (9) · Doxorubicin (6) · Leucovorin (4) · Docetaxel (4) · SR Mitomycin Intravesical Solution (4)
Related medicines
As reviewed, each with the page that says it.
- One of Alkylating agents source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Tested against it · 6 phase 3 studies under way
Mitomycin is the comparator. A study of two new drugs counts under both.
- 1Gemcitabine-Releasing Intravesical System · Janssen Research & Development, LLC · next primary completion Nov 2030
- 1Enfortumab vedotin · Astellas Pharma Global Development, Inc. · next primary completion Mar 2030
- 1Pembrolizumab · Astellas Pharma Global Development, Inc. · next primary completion Mar 2030
- 1Efserakefusp alfa · Suzhou Suncadia Biopharmaceuticals Co., Ltd. · next primary completion Jun 2030
- 1Sintilimab · Cancer Institute and Hospital, Chinese Academy of Medical Sciences · next primary completion Mar 2029
Reaching primary completion within a year · 9, 2 in phase 3
Studies that test Mitomycin, phase 3 first.
- Dec 2026BCG + MMC: Adding Mitomycin C to BCG in High-risk, Non-muscle-invasive Bladder CancerPhase 3 · Nottingham University Hospitals NHS Trust
- Jun 2027Investigating the Efficacy and Safety of Neoadjuvant Intravesical Instillation of Mitomycin C in Treating High-risk NMIBC PatientsPhase 3 · Shaogang Wang
- Dec 2026Guiding Instillation in Non Muscle-invasive Bladder Cancer Based on Drug Screens in Patient Derived OrganoidsPhase 2 · Roland Seiler-Blarer
- Dec 2026Adaptive Radiation in Anal CancerNot applicable · Columbia University
- Jan 2027Clinical Trial Evaluating Low Dose G-FLIP Plus Mitomycin C for Stage IV Pancreatic CancerPhase 2 · Hirschfeld Oncology
- Sep 2027ICARuS Post-operative Intraperitoneal Chemotherapy (EPIC) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) After Optimal Cytoreductive Surgery (CRS) for Neoplasms of the Appendix, Colon or Rectum With Isolated Peritoneal MetastasisPhase 2 · Memorial Sloan Kettering Cancer Center
- Sep 2027Bladder Preservation or Cystectomy for MIBCEarly Phase 1 · Dana-Farber Cancer Institute
- Oct 2027Toripalimab ± Sequential Intravesical Gemcitabine-Mitomycin C for BCG-Unresponsive/-Intolerant High-Risk NMIBC: Open-Label Randomized Phase 2 StudyPhase 2 · First Affiliated Hospital of Wenzhou Medical University
- Oct 2027Phase II Trial of Lung ChemoemobolizationPhase 2 · City of Hope Medical Center
Studies
Open first, then newest update. How each study uses Mitomycin is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 134
- The Clinical Effectiveness and Safety of Intravesical Mitomycin-C and Gemcitabine Sequential TherapyRecruitingPhase 2National Cancer Center, KoreaNCT06388720Written as Mitomycin-C
- Individual Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal HistologiesRecruitingPhase 1National Cancer Institute (NCI)NCT04847063Written as Mitomycin C
- Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colorectal Cancer With Peritoneal Metastases, The IMPACT TrialRecruitingPhase 3City of Hope Medical CenterNCT07271355Written as Mitomycin
- Risk-Enabled Therapy After Initiating EV/Pembro for Bladder CancerRecruitingPhase 2Fox Chase Cancer CenterNCT07908979Written as Mitomycin c
- Combined Systemic and Intraperitoneal Chemotherapy for Synchronous Gastric and/or Gastroesophageal Peritoneal CarcinomatosisRecruitingPhase 2Mohammad Haroon Asif ChoudryNCT07475286Written as Mitomycin C
- In-home Intravesical Chemotherapy for the Treatment of Bladder Cancer, INVITE TrialRecruitingPhase 1/2Mayo ClinicNCT06704191Written as Mitomycin
- Precise Chemoresection in Low-grade NMIBC Using Drug Screens in Patient-derived OrganoidsNot yet recruitingPhase 2Hospital Centre Biel/BienneNCT06227065Written as Mitomycin
- Safety and Efficacy of PIPAC Using Single Agent Mitomycin in Solid TumorsRecruitingPhase 1H. Lee Moffitt Cancer Center and Research InstituteNCT07487168Written as Mitomycin C (MMC)
- Toripalimab ± Sequential Intravesical Gemcitabine-Mitomycin C for BCG-Unresponsive/-Intolerant High-Risk NMIBC: Open-Label Randomized Phase 2 StudyNot yet recruitingPhase 2First Affiliated Hospital of Wenzhou Medical UniversityNCT07189793Written as Mitomycin C (MMC)
- Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric CancerRecruitingPhase 2University of ChicagoNCT04107077Written as Mitomycin
- PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric CancerRecruitingPhase 1City of Hope Medical CenterNCT04329494Written as Mitomycin
- Metronomic Gemcitabine, Mitomycin C, and Thalidomide for Advanced Solid TumorsRecruitingPhase 2Sarcoma Oncology Research Center, LLCNCT07671534Written as Mitomycin C
- Efficacy of the Use of Neoadjuvant With/Without Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Locally Advanced Colon CancerRecruitingPhase 3Maimónides Biomedical Research Institute of CórdobaNCT06783491Written as Mitomycin (MM)
- Phase II Trial of Lung ChemoemobolizationRecruitingPhase 2City of Hope Medical CenterNCT05672108Written as Mitomycin
- Study to Evaluate the Non-inferiority of Low-dose HIPEC Versus High-dose HIPEC in the Treatment of PMP (HIPEC-PMP)RecruitingPhase 3University of SouthamptonNCT06513065Written as Mitomycin c
- Adaptive Radiation in Anal CancerRecruitingNot applicableColumbia UniversityNCT05838391Written as Mitomycin-C
- Chemoablation Or Bladder Resection With Adjuvant Chemotherapy in Recurrent Non-Muscle Invasive Bladder CancerRecruitingPhase 4Jakob Kristian JakobsenNCT06781879Written as Mitomycin c
- Investigating the Efficacy and Safety of Neoadjuvant Intravesical Instillation of Mitomycin C in Treating High-risk NMIBC PatientsRecruitingPhase 3Shaogang WangNCT06696794Written as Mitomycin C (MMC)
- Effect of Mitomycin-C on the Outcomes of Patients Receiving Ahmed Glaucoma Valve Implantation SurgeryNot yet recruitingPhase 3St. Joseph's Healthcare HamiltonNCT06680245Written as Mitomycin c
- Clinical Trial Evaluating Low Dose G-FLIP Plus Mitomycin C for Stage IV Pancreatic CancerNot yet recruitingPhase 2Hirschfeld OncologyNCT06233877Written as G-GLIP plus Mitomycin C
See all 134 studies that test Mitomycin →
Given beside what is tested · 16 — Mitomycin is usual care or a partner of the new treatment
- A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) and Pembrolizumab (MK-3475A) in Participants With Bladder Cancer (MK-2870-055)RecruitingPhase 3Merck Sharp & Dohme LLCNCT07829783Written as MMC
- Disitamab Vedotin Plus Intravesical Mitomycin C in HER2-Expressing Intermediate- to High-Risk Non-Muscle-Invasive Bladder CancerRecruitingPhase 2Shanxi Province Cancer HospitalNCT07646145Written as Mitomycin C (MMC)
- Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER StudyRecruitingPhase 3NRG OncologyNCT07097142Written as Mitomycin
- Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder CancerActive, not recruitingPhase 3National Cancer Institute (NCI)NCT03775265Written as Mitomycin
- External Versus Powered Endoscopic Dacryocystorhinostomy With Mitomycin C for Primary Acquired Nasolacrimal Duct ObstructionCompletedNot applicableMilitary Institute od Medicine National Research InstituteNCT07754058Written as Mitomycin C 0.02%
- Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)Active, not recruitingPhase 3Merck Sharp & Dohme LLCNCT04241185Written as Mitomycin C (MMC)
- Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by SurgeryCompletedPhase 3National Cancer Institute (NCI)NCT01004978Written as Mitomycin
- CAVATAK (CVA21) in Non-muscle Invasive Bladder Cancer (VLA-012 CANON)CompletedPhase 1ViralyticsNCT02316171Written as Mitomycin C
- Topical MTS-01 for Dermatitis During Radiation and Chemotherapy for Anal CancerTerminatedPhase 1National Cancer Institute (NCI)NCT01324141Written as Mitomycin-C
- Effects of Deep Regional Hyperthermia in Patients With Anal Carcinoma Treated by Standard RadiochemotherapyStatus unknownPhase 3University of Erlangen-Nürnberg Medical SchoolNCT02369939Written as Mitomycin C
- Veliparib With or Without Mitomycin C in Treating Patients With Metastatic, Unresectable, or Recurrent Solid TumorsCompletedPhase 1National Cancer Institute (NCI)NCT01017640Written as Mitomycin
- Combine TACE and RFA Versus TACE Alone for HCC With PVTTStatus unknownPhase 3Ming ZhaoNCT02301091Written as pirarubicin,mitomycin and lobaplatin
- Trial of ICM With or Without AZD2281 (Olaparib) in Patients With Advanced Pancreatic CancerCompletedPhase 1Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT01296763Written as Mitomycin-C
- Immunotherapy Using Precision T Cells Specific to Multiple Common Tumor-Associated Antigen Combined With Transcatheter Arterial Chemoembolization for the Treatment of Advanced Hepatocellular CarcinomaStatus unknownPhase 1/2Second Military Medical UniversityNCT02638857Written as Mitomycin (MMC)
- Trial of Adjuvant Chemotherapy for Gastric CancerCompletedPhase 3Asan Medical CenterNCT00296335Written as Mitomycin, doxifluridine and cisplatin
- Sorafenib Tosylate and Chemoembolization in Treating Patients With Unresectable Liver CancerCompletedPhase 1Abramson Cancer Center at Penn MedicineNCT01042041Written as mitomycin C
As the comparator · 24 — what is tested is compared with Mitomycin
- Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC TrialRecruitingPhase 2National Cancer Institute (NCI)NCT06770582Written as Mitomycin
- A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder CancerRecruitingPhase 3Janssen Research & Development, LLCNCT06319820Written as MMC
- A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder CancerRecruitingPhase 3Janssen Research & Development, LLCNCT06919965Written as Mitomycin C
- Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)RecruitingPhase 3Astellas Pharma Global Development, Inc.NCT07566156Written as Mitomycin C
- A Study of Intravesical SHR-1501 Combination With BCG Versus Investigator-selected Chemotherapy in Subjects With BCG-unresponsive NMIBCRecruitingPhase 3Suzhou Suncadia Biopharmaceuticals Co., Ltd.NCT07424287Written as Mitomycin for Injection
- Sintilimab Versus Mitomycin in Combination With Capecitabine and IMRT for Limited-stage Anal Squamous Cell CarcinomaRecruitingPhase 3Cancer Institute and Hospital, Chinese Academy of Medical SciencesNCT07692152Written as Mitomycin (MMC)
- Hyaluronic Acid vs Mitomycin-C in External DacryocystorhinostomyNot yet recruitingPhase 4All India Institute of Medical Sciences, BhubaneswarNCT07504250Written as Mitomycin -C
- Comparing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS-HIPEC) Using Mitomycin-C Versus Melphalan for Colorectal Peritoneal CarcinomatosisRecruitingPhase 2University of Kansas Medical CenterNCT03073694Written as Mitomycin c
- Clinical Study of Curcumin in Preventing Postoperative Adhesion of Bilateral Vocal CordsRecruitingPhase 1/2Eye & ENT Hospital of Fudan UniversityNCT05688488Written as Mitomycin-C
- A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG)Active, not recruitingPhase 3Janssen Research & Development, LLCNCT06211764Written as Mitomycin C
- Therapeutic Instillation of MistletoeTerminatedPhase 3Abnoba GmbhNCT02106572Written as Mitomycin C
- SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast CancerActive, not recruitingPhase 2UNICANCERNCT02299999Written as Mitomycin C
- Comparison of Efficacy and Safety of Mitomycin and Aflibercept Used to Support Primary Trabeculectomy.CompletedEarly Phase 1Medical University of LublinNCT03766425Written as Mitomycin
- Study to Evaluate the Efficacy and Safety Of Intravesical Nanoxel®M In BCG Refractory NMIBCTerminatedPhase 3Samyang Biopharmaceuticals CorporationNCT02982395Written as Mitomycin-C
- Decorin in Sub Scleral TrabeculectomyStatus unknownPhase 1Cairo UniversityNCT03924544Written as Mitomycin c
- Phacotrabeculectomy With Collagen Matrix Implant (Ologen®) Versus Mitomycin CCompletedPhase 2Medical University of LublinNCT03506542Written as Mitomycin C
- Lucentis Versus Mitomycin C During Glaucoma SurgeryCompletedPhase 2/3Wills EyeNCT00626782Written as Mitomycin (MMC)
- Efficacy and Safety Evaluation of EN3348 (Mycobacterial Cell Wall-DNA Complex [MCC]) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent/Refractory Non-muscle Invasive Bladder CancerTerminatedPhase 3Bioniche Life Sciences Inc.NCT01200992Written as Mitomycin C
- Safety Study of Avastin Used as Adjunctive Therapy in Pterygium SurgeryCompletedPhase 2The University of Texas Health Science Center, HoustonNCT01115517Written as Mitomycin C
- Use of Ranibizumab With Mitomycin C During TrabeculectomyCompletedPhase 1/2University of Colorado, DenverNCT00661583Written as MMC
Showing 20 of 24.
What changed recently
From the registry's own updates since Oct 20, 2026.
Results posted1
Newly registered1
- Risk-Enabled Therapy After Initiating EV/Pembro for Bladder CancerNov 2, 2026NCT07908979
Codes
What other systems call Mitomycin · ClinicalTrials.gg INT008539
- MeSH (NLM) D016685MitomycinConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 50SG953SK6MITOMYCINConfirmed FDA, NLM, Wikidata
- RxNorm 632Confirmed FDA, Wikidata
- Wikidata Q19856779mitomycinConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C1820MitomycinOne source FDA
- DrugBank DB00305One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D016685 | Mitomycin | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 50SG953SK6 | MITOMYCIN | Confirmed FDA, NLM, Wikidata |
| RxNorm | 632 | — | Confirmed FDA, Wikidata |
| Wikidata | Q19856779 | mitomycin | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C1820 | Mitomycin | One source FDA |
| DrugBank | DB00305 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.